COVID-19 has been declared as a global pandemic by the World Health Organization.[@bib1]^,^[@bib2] COVID-19 is a clinical syndrome caused by SARS-CoV-2. The hallmark of COVID-19 is respiratory involvement, ranging from mild upper respiratory symptoms to acute respiratory distress syndrome (ARDS).[@bib2] However, severe COVID-19 imparts multiorgan involvement, with several observational case series showing a significant proportion of cardiac involvement among hospitalized patients.[@bib3]^,^[@bib4] In addition, cardiac injury has shown disproportionate rates of mortality, with rates approaching 51% when cardiac involvement has been established.[@bib3] COVID-19 has a wide spectrum of cardiovascular complications, including acute-onset heart failure, arrhythmias, acute coronary syndrome, myocarditis, and cardiac arrest.[@bib3]^,^[@bib4] Myocarditis is a potentially lethal complication, observed among cases of the current and previous outbreaks of other coronaviridae, such as MERS.[@bib5], [@bib6], [@bib7], [@bib8] Because of the relative novelty of COVID-19, the data surrounding the association between COVID-19 and myocarditis are still being published. The aim of this review was to examine the most updated literature surrounding COVID-19 and myocarditis.

What Pathophysiologic Mechanisms Are Involved in COVID-19-Associated Cardiac Disease? {#sec1}
=====================================================================================

The exact pathophysiology of severe COVID-19 disease is still elusive. However, a consistent observation is the presence of a proinflammatory surge, the so-called "cytokine storm." This is thought to be central to the pathogenesis of the acute lung injury-acute respiratory distress syndrome spectrum that amplifies the immune response of alveolar tissue.[@bib9], [@bib10], [@bib11] This phenomenon is thought to be a contributory factor to myocardial injury, observed in other forms of viral infections, such as H1N1.[@bib12] Huang et al.[@bib9] showed this among a cluster of 41 patients with COVID-19. Patients who required intensive care (n = 13) showed higher plasma concentrations of cytokines and chemokines, including GCSF, IP10, MCP1, MIP1A, and tumour necrosis factor α. However, it is unknown if myocarditis is the actual cause of the troponin increase in this case series, because the authors did not report data showing correlative cardiac outcomes or demonstration of left ventricular dysfunction.

Chen and colleagues also had a similar observation, with elevation of interleukin (IL)-2R, IL-6, IL-10, and tumour necrosis factor α among the cohort of severe COVID-19 patients in a single-centre retrospective study.[@bib11] Cytokine storm is not unique to severe COVID-19, because MERS-CoV and SARS-CoV have shown cytokine surge syndrome among the spectrum of coronavirus disease.[@bib13]^,^[@bib14] Whether this phenomenon is the main cause of fulminant myocarditis still uncertain ([Fig. 1](#fig1){ref-type="fig"}).Figure 1Mechanisms of pathogenesis and systemic effects of COVID-19 leading to multiorgan damage. ARDS, acute respiratory distress syndrome; CCL2, C-C motif chemokine ligand 2; CCL3, C-C motif chemokine ligand 3; IL, interleukin 1; SARS-COV2, severe acute respiratory syndrome coronavirus 2; TNF, tumour necrosis factor α.

It is currently unknown whether the response is purely related to inflammation, autoimmunity, or a combination of both as seen in other types of viral myocarditis.[@bib15]

Another potential cause of myocarditis is direct viral involvement. SARS-CoV-2 uses the angiotensin-converting enzyme 2 via its S-spike to bind and anchor to the receptors, hence an entry point to the cell.[@bib16]^,^[@bib17] Hence, it is reasonable to consider viral inclusion or associated myocardial inflammation as the pathogenesis of myocarditis. This direct myocardial involvement was seen in MERS, with one report showing evidence of subepicardial late gadolinium enhancement, consistent with myocarditis.[@bib6] In this case, the distribution of late gadolinium enhancement in the subepicardial region is consistent with myocarditis.

So far, there are limited reports showing pathological evidence that COVID-19 directly invades the heart.[@bib18] Sala et al. showed viral particles with the morphology and size of coronaviruses in interstitial macrophages, however, there was no SARS-CoV-2 genomic material in the myocardium. In another study, Xu et al. reported pathological postmortem biopsies from a patient who succumbed to COVID-19. There were only a few interstitial mononuclear inflammatory infiltrates, but no other substantial damage in the heart tissue.[@bib4]

How Common Is Cardiac Involvement in Patients With COVID-19? {#sec2}
============================================================

Outside of published case reports, the exact incidence of myocardial involvement or myocarditis among hospitalized COVID-19 patients is unknown. However, several observational studies have reported cardiac injury among hospitalized COVID-19 patients.[@bib3]^,^[@bib19]^,^[@bib20] In most reports myocardial injury is defined as detectable serum troponin level above the 99th percentile of the upper reference limit. So far, the largest study to examine the association between cardiac involvement and COVID-19 was performed at the index epicentre in China.[@bib3] From a cohort of 416 patients at the Renmin Hospital of Wuhan University, 82 patients (19.7%) had cardiac injury. Mortality among the myocardial injury group was significantly higher (51.2% vs 4.5%; *P* \< 0.001). Cardiac involvement among this cohort of patients showed a hazard ratio of 4.26. Ruan et al. reported a multicentre, retrospective review of 150 patients with confirmed COVID-19.[@bib20] Sixty-eight patients died, with 5 patients (7%) dying of heart failure and 22 patients (33%) dying of respiratory and heart failure. The cohort with a higher rate of death consistently had higher levels of troponin and myoglobin. The authors speculate that some of these patients died of COVID-19-induced fulminant myocarditis, but no reports on autopsies or biopsies were provided.

What Are the Symptoms of Myocarditis Among COVID-19 Patients? {#sec3}
=============================================================

Myocarditis can have a variety of clinical presentations, ranging from mild symptoms such as fatigue, chest pain, and palpitations to life-threatening presentations such as cardiogenic shock or sudden cardiac death associated with ventricular arrhythmias ([Fig. 2](#fig2){ref-type="fig"}).[@bib21] Classically, myocarditis has a viral prodrome including fevers, myalgias, and respiratory/gastrointestinal symptoms but this can be exceedingly variable, with ranges of 10%-80%.[@bib22]^,^[@bib23] Myocarditis is more common in men, with a male/female ratio between 1.5:1 and 1.7:1.[@bib24]Figure 2Clinical presentations of patients with biopsy-proven inflammatory heart muscle disease. AV, atrioventricular; CAD, coronary artery disease; CMR, cardiac magnetic resonance; DCM, dilated cardiomyopathy; ECG, electrocardiogram; LV, left ventricular; RV, right ventricular; TnI, troponin I; TnT, troponin T. Modified from Caforio et al.[@bib21] with permission from Oxford University Press.

COVID-19 patients predominantly present with fever, cough, and dyspnea.[@bib23] A meta-analysis of 10 studies including 1995 COVID-19 patients showed that common symptoms were fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%); minor symptoms included headache or dizziness (12.1%), diarrhea (4.8%), and nausea and vomiting (3.9%).[@bib23] Other infrequent symptoms such as abdominal pain, constipation, chest pain, palpitations, chills, and anorexia accounted for 7%-42% of presentations altogether.[@bib21]

A cohort study from Wuhan, China involving 416 hospitalized patients with confirmed COVID-19 infection showed that chest pain accounted for 3.4% of presentations.[@bib3] Hospitalized patients with an increase of troponin level were more likely to present with chest pain than those without an increase of troponin level (11 of 82 patients \[13.4%\] vs 3 of 334 patients \[0.9%\]; *P* \< 0.001). Established myocarditis is a relatively rare sequelae of COVID-19 infection. In the reported COVID-19 cases with myocarditis in the literature, clinical presentations have varied ([Table 1](#tbl1){ref-type="table"}). There is potential overlap in symptomatology in patients with primary COVID-19 infection and COVID-19 patients with clinically suspected myocarditis.Table 1Published literature highlighting clinically suspected myocarditis in COVID-19 patientsStudyCaseClinicalTroponinNT-proBNPECGTTECMREMBOutcomeInciardi et al.[@bib7]53 MCough\
Fatigue\
FeverTroponin T: 0.24 ng/mL5647 pg/mLMinimal diffuse ST segment elevation (more prominent in inferolateral leads) and ST depression with T wave inversion in lead V~1~ and aVRLVEF 40%Short tau inversion recovery and T2 mapping sequences showing biventricular myocardial interstitial edema. Inversion recovery sequences showing biventricular wall diffuse LGEN/AClinical improvementZeng et al.[@bib5]63 MChest pain\
Cough\
Dyspnea\
Fever\
SputumTroponin I: 11.37 g/L22,600 pg/mLSinus tachycardia, no ST elevationLVEF 32%N/AN/AECMO as a bridge to clinical recoveryHu et al.[@bib8]37 MChest pain\
Diarrhea\
DyspneaTroponin T: \> 10,000 ng/L21,025 ng/LST segment elevation in lead 3, aVFLVEF 27%N/AN/AClinical recoveryTavazzi et al.[@bib18]69 MCough\
Dyspnea\
WeaknessTroponin I: 4331 ng/LN/AN/ALVEF 34%N/ACD68^+^ macrophages with viral particles noted. No virus in cardiac myocytesDeath from bacterial sepsisSala et al.[@bib36]43 FChest pain\
DyspneaTroponin T: 135 ng/L512 pg/mLAtrial ectopic rhythm, mild ST segment elevation in V~1~, V~2~, aVR; reciprocal ST depression in V~4~-V~6~LVEF 43%Basal and mid-LV hypokinesis with diffuse myocardial edema. LGE showed absence of scar and necrosisDiffuse T-lymphocytic inflammatory infiltrates with interstitial edema and limited necrosis. No viral genome in myocardiumClinical recoveryDoyen et al.[@bib37]69 MCough\
Diarrhea\
Dyspnea\
Fever\
VomitingTroponin I: 9002 ng/LN/ACriteria for left ventricular hypertrophy and diffuse inverted T wavesLVEF \> 50%Subepicardial LGE of the apex and inferolateral wallN/AClinical recoveryCoyle et al.[@bib38]57 MCough\
Diarrhea\
Dyspnea\
Fever\
NauseaTroponin I: 7.33 ng/mL1300 pg/mLSinus tachycardia, no ST-T wave changesLVEF 35%-40%Diffuse biventricular and biatrial edema with a small area of LGEN/AClinical recoveryLuetkens et al.[@bib39]79 MDyspnea\
Fatigue\
SyncopeTroponin T: 63.5 ng/L1178 pg/mLNormalLVEF \> 50%Diffuse interstitial myocardial edema with an increased T2 signal intensity ratio. T2 mapping showed diffuse myocardial inflammationN/AClinical recoveryKim et al.[@bib40]21 FCough\
Diarrhea\
Dyspnea\
Fever\
SputumTroponin I: 1.26 ng/mL1929 pg/mLNonspecific interventricular conduction delay and multiple premature ventricular complexesLVEF \< 35%Diffuse high signal intensity in the LV myocardium on T2 short tau inversion recovery image, and myocardial wall edema. Extensive transmural LGEN/AN/A[^1]

How Can Myocarditis Among COVID-19 Patients Be Diagnosed? {#sec4}
=========================================================

Significant serum troponin elevation has been observed among several cases of severe COVID-19, which might indicate cardiac involvement.[@bib25] A study by Zhou et al. showed that high-sensitivity troponin I levels were significantly greater by day 4 in COVID-19 nonsurvivors vs survivors (8.8 pg/mL vs 2.5 pg/mL). Myocardial injury is a predictor of mortality and more severe illness in COVID-19-confirmed patients.[@bib26] However, troponitis in isolation is not diagnostic of myocarditis and requires other supplementary findings and investigations. Furthermore, troponin elevation in the setting of severe COVID-19 could be a reflection of supply demand mismatch, rather than overt myocardial injury.[@bib27] Other biomarkers, such as natriuretic peptides are not sensitive or specific in diagnosing myocarditis.[@bib21]

Electrocardiograms (ECGs) are usually abnormal in patients with myocarditis, however, specific abnormalities on ECG lack sensitivity and specificity.[@bib28] Dynamic ECG changes have been documented in critically ill COVID-19 patients.[@bib29] In 2 cases reported by He et al., dynamic ECG changes were noted when hospitalized COVID-19 patients clinically deteriorated.[@bib29] In one case, a patient's baseline ECG was sinus rhythm with first-degree atrioventricular (AV) block, which progressed to high-grade AV block before returning to baseline within 2 days. It was undetermined if these patients had myocarditis. Nevertheless, dynamic ECG changes in COVID-19 patients might be a harbinger of clinical deterioration and should be recorded in all hospitalized COVID-19 patients.

Echocardiography is an important first-line noninvasive test in the workup for myocarditis. Transthoracic echocardiography (TTE) can help rule out other causes of heart failure such as myocardial infarction and valvular heart disease.[@bib30] TTE findings can include global left ventricular hypokinesis, regional wall motion abnormalities, and dilated and/or hypertrophic ventricles.[@bib31] In the case reports of suspected myocarditis in COVID-19 patients ([Table 1](#tbl1){ref-type="table"}), all TTEs revealed reduced left ventricular ejection fraction. Given the need for close contact to obtain images, the Canadian Society of Echocardiography recommends that among COVID-19-positive or suspected patients, point-of-care ultrasound should be highly considered as an initial screening test.[@bib32] Subsequently the initial findings would determine whether a definitive TTE is required.

In typical circumstances, before the COVID-19 pandemic, cardiac magnetic resonance (CMR) imaging is an integral test in the diagnosis of myocarditis, especially if endomyocardial biopsy (EMB) is not pursued or cannot be obtained.[@bib33] CMR using the Lake Louise criteria has a specificity of up to 91% and a sensitivity of 67% for diagnosing myocarditis.[@bib34] CMR is not indicated in unstable patients who present with severe heart failure, circulatory shock, ventricular arrhythmia, or high-grade AV block and an EMB should be obtained.[@bib34] If CMR is available and there are no contraindications to testing, CMR can safely be used as a first-line diagnostic tool in the workup of myocarditis associated with COVID-19.[@bib35] This is documented in the current literature, because several authors have used CMR imaging to fulfil the Lake Louise criteria for diagnosing patients with myocarditis associated with COVID-19.[@bib7]^,^[@bib18]^,^[@bib36], [@bib37], [@bib38], [@bib39], [@bib40] Clinical reasoning should drive the pursuit of definitive investigations when COVID-19 myocarditis is suspected.

EMB is recommended, but is not required, in certain clinical situations to aid in the diagnosis of myocarditis.[@bib24] Histologic analysis typically reveals inflammatory infiltrates with myocyte degeneration and nonischemic necrosis.[@bib21] Xu et al. were the first to report interstitial mononuclear inflammatory infiltrates in a postmortem biopsy of a COVID-19 patient.[@bib4] In another histopathologic study involving 3 patients, all patients had small amounts of lymphocyte, monocyte, and neutrophil infiltration in heart tissue but polymerase chain reaction did not detect COVID-19 in myocardial tissue.[@bib41] A case reported by Sala et al. showed diffuse T-lymphocytic inflammatory infiltrates (CD3^+^ \> 7/mm^2^) with interstitial edema, but no COVID-19 genome in the myocardium.[@bib36]Furthermore, Tavazzi et al. showed viral particles typical of coronavirus involving interstitial macrophages and their surroundings, but not within the cardiac myocytes.[@bib18] Myocarditis can be an incidental finding in autopsy studies of patients who died from a noncardiac cause. Therefore, the implication of finding myocardial inflammation should always be interpreted in the context of specific clinical scenarios.[@bib19] To date, EMB evidence of direct viral invasion into myocardium has not been shown in cases of suspected COVID-19 myocarditis, which is limited by a paucity of published pathologic data.

To summarize, there is no single test or exam that allows for diagnosis of myocarditis, because the diagnosis requires a combination of clinical findings, biomarkers, imaging, and pathology when indicated.

How Can Myocarditis Be Treated Among Patients With Severe COVID-19? {#sec5}
===================================================================

There are some randomized controlled trial (RCT) data regarding management of myocarditis patients, and guideline recommendations are on the basis of expert consensus.[@bib42] Patients with suspected myocarditis due to COVID-19 should be treated according to current guideline recommendations for heart failure and arrhythmia.[@bib21]^,^[@bib33]^,^[@bib42] Heart failure is common (\> 20%) in hospitalized COVID-19 patients and it is unclear whether this is primarily due to deterioration of preexisting left ventricular function, new-onset myocarditis, or a combination of factors.[@bib26]

The routine use of steroids and other immunosuppressive strategies in all patients with myocarditis is not recommended.[@bib33] The Myocarditis Treatment Trial is the largest RCT to study immunosuppression in patients with myocarditis, which randomized 111 patients with EMB-proven myocarditis to prednisone with azathioprine, prednisone with cyclosporine, and placebo.[@bib43] There was no statistical difference in the primary end point of left ventricular ejection fraction at 28 weeks.

Systemic steroids and immunosuppression are not currently recommended for COVID-19 patients because it might exacerbate COVID-19-associated lung injury.[@bib44] A subset of these patients present with cytokine storm, and emerging data show that immunosuppression might be beneficial in these patients.[@bib10] There are ongoing clinical trials with options including steroids, intravenous immunoglobulin, selective cytokine blockade (eg, anakinra or tocilizumab), and JAK inhibition (ChiCTR2000029765).[@bib45] Although the cases of COVID-19 patients with myocarditis were treated with steroids, it is unclear the incremental benefit these therapies might have provided over supportive care. There is insufficient evidence to recommend systemic immunosuppression for suspected COVID-19 myocarditis at this time.

Antiviral therapy has been used previously in patients with viral myocarditis. However, RCTs of these therapies have not established myocarditis-causing viruses, such as enterovirus or adenovirus, as therapeutic targets.[@bib46] For example, the **B**etaferon in **C**hronic **V**iral **C**ardiomyopathy (BICC) trial randomized patients with EMB-confirmed viral cardiomyopathy to receive placebo or interferon-B. Viral clearance was not enhanced in all virus subtypes. Antiviral therapy is under investigation for the treatment of COVID-19. Lopinavir/ritonavir is a combination antiviral agent, primarily used for treatment of HIV, which is undergoing clinical trials for COVID-19. One RCT did not show any benefit in mortality compared with placebo, and lopinavir/ritonavir can be associated with long QT interval.[@bib47] To date, there is no antiviral therapy that is known to be of benefit to COVID-19 patients.

As shown in [Table 1](#tbl1){ref-type="table"}, published case reports highlight the variability in presentation of COVID-19-associated myocarditis. However, supportive therapy is still the current mainstay of management, because there is still no clear signal that any combination of immunosuppression improves outcomes among patients with myocarditis. This variability in practice is highlighted in the published case series. Steroid monotherapy,[@bib7]^,^[@bib37] steroid and IL-6 inhibitor combination therapy,[@bib38] and antiviral monotherapy with no immunomodulation[@bib5] have all been used to date in cases of COVID-19-associated myocarditis. The benefits of immunosuppression in treating contemporary fulminant myocarditis are yet to be determined. [Figure 3](#fig3){ref-type="fig"} shows a summary of the general clinical approach among published case reports of COVID-19-associated myocarditis.Figure 3Summary of clinical approach of published cases of myocarditis associated with COVID-19. BNP, B type natriuretic peptide; CMR, cardiac magnetic resonance; ECG, electrocardiogram; EF, ejection fraction; IL, interleukin; LGE, late gadolinium enhancement.

Patients with myocarditis can clinically deteriorate or develop end-organ dysfunction despite standard heart failure therapy and supportive care. Before the COVID-19 pandemic, cases of end-stage, non-COVID-19-associated myocarditis could be referred for mechanical circulatory support (MCS) and/or consideration of heart transplantation.[@bib33] MCS as a bridge to recovery has been successful in fulminant myocarditis.[@bib48] Zhang et al. reported the first case of fulminant myocarditis requiring MCS with extracorporeal membrane oxygenator as a successful bridge to recovery in a COVID-19 patient.[@bib45] Heart transplantation would not be an option for patients with COVID-19-associated myocarditis because of their active and ongoing infection.[@bib33]

Summary and Future Directions {#sec6}
=============================

Myocardial injury is common in patients with COVID-19, accounting for 7%-23% of reported cases in Wuhan, China.[@bib9]^,^[@bib49]^,^[@bib50] Among COVID-related myocardial injury, etiologies vary and are can include myocarditis, myocardial infarction, sepsis-related myocardial injury, and/or stress-induced cardiomyopathy.[@bib51] Further prospective cohort and case series data are needed to better characterize the exact mechanism of injury in myocarditis related to COVID-19. Because of the low prevalence of disease, this will most likely require multisite collaboration and endeavours.

Clinically suspected myocarditis is a rare cause of myocardial injury, has heterogeneous clinical presentations, and is likely underdiagnosed in critically ill patients with COVID-19. Because of the potential for rapid deterioration in COVID-19 patients with myocarditis, it is imperative to be aware of myocarditis as a sequela of COVID-19 and a multidisciplinary team should be formed for all COVID-19 patients with clinically suspected myocarditis. Further studies are needed to better recognize and understand the association of myocarditis and COVID-19.
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[^1]: CMR, cardiac magnetic resonance; ECG, electrocardiogram; ECMO, extracorporeal membrane oxygenator; F, female; EMB, endomyocardial biopsy; LGE, late gadolinium enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction, M, male; N/A, not available; NT-proBNP, N terminal pro B type natriuretic peptide; TTE, transthoracic echocardiography.
